Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXM1 | Q08050 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 16/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ESRRA | P11474 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698902 | 1.00 | FOXM1 (0.61) | FOXM1PTPN1HPGDESRRASRD5A1 | |
| SCHEMBL2701595 | 0.91 | FOXM1 (0.50) | FOXM1PTPN1HPGDESRRASRD5A1 | |
| SCHEMBL2701599 | 0.91 | FOXM1 (0.50) | FOXM1PTPN1HPGDESRRASRD5A1 | |
| SCHEMBL2699653 | 0.89 | FOXM1 (0.69) | FOXM1PTPN1HPGDESRRA | |
| SCHEMBL2699658 | 0.89 | FOXM1 (0.69) | FOXM1PTPN1HPGDESRRA | |
| SCHEMBL2699391 | 0.89 | HPGD (0.62) | FOXM1PTPN1HPGD | |
| SCHEMBL2699394 | 0.89 | HPGD (0.62) | FOXM1PTPN1HPGD | |
| SCHEMBL4278982 | 0.84 | HPGD (0.59) | FOXM1PTPN1HPGD | |
| SCHEMBL2699811 | 0.82 | FOXM1 (0.65) | FOXM1PTPN1HPGDESRRA | |
| SCHEMBL2699814 | 0.82 | FOXM1 (0.65) | FOXM1PTPN1HPGDESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | FOXM1 206/4885PTPN1 442/4885HPGD 485/4885 |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | FOXM1 206/4885PTPN1 442/4885HPGD 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.